Eurocine Vaccines discloses interim report for July 2022 – March 2023
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) hereby discloses the interim report for July 2022 to March 2023. Below is a summary of…
Eurocine Vaccines receives grant from Merck Group
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) announces today that the Company has received a grant of SEK 300,000 from Merck Group (“Merck”).Read…
Eurocine Vaccines discloses half-year report for July – December 2022
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) hereby discloses the half-year report for July to December 2022. Below is a summary of the…
Eurocine Vaccines’ Director of Preclinical Development invited to lecture at UCL School of Pharmacy
Eurocine Vaccines (“Eurocine” or the “Company”) announces today that the Company’s Director of Preclinical Development, Dr. Karl Ljungberg, has lectured on DNA and RNA vaccines…
Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia
In the pursuit of the most advanced vaccines of high potential, the board of Eurocine Vaccines has decided to develop a vaccine candidate against chlamydia…
Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate
As communicated earlier, Eurocine Vaccines is conducting preclinical trials to evaluate the mRNA and protein technology platforms for its therapeutic Herpes simplex virus type 2,…
Eurocine Vaccines´ newly added HSV-2 vaccine candidate gains patent protection in South Korea
Eurocine Vaccines has received a Notice of Decision to Grant from the Korean Intellectual Property Office, covering inventions relevant for the newly added vaccine candidate…
Eurocine Vaccines discloses year-end report for the fiscal year 2021/2022
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby discloses the year-end report for the fiscal year 2021/2022. Below is a summary of the report. The full…
Disclosure notice in Eurocine Vaccines
Eurocine Vaccines AB hereby announces that Flerie Invest AB has acquired shares in the company and now holds more than 15 % of the shares.…
Eurocine Vaccines outlines a strategic development plan for its newly added therapeutic HSV-2 vaccine candidate
Expanding its portfolio, Eurocine Vaccines adds considerable value by the new HSV-2 vaccine candidate, which holds significant market potential. Currently, Herpes Simplex Virus Type 2,…